Article
Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer.
International journal of clinical oncology - 1 Aug 2013
Soeda Hiroshi, Shimodaira Hideki, Watanabe Mika, Suzuki Takao, Gamoh Makio, Mori Takahiro, Komine Keigo, Iwama Noriyuki, Kato Shunsuke, Ishioka Chikashi
Abstract excerpt
BACKGROUND: Anti-epidermal growth factor receptor (EGFR) antibodies, cetuximab, and panitumumab are established as a new treatment option for metastatic colorectal cancer (mCRC). Among activating mutations downstream of EGFR, the KRAS mutation, which is present in 30-45 % of CRC patients, has shown to be a predictive biomarker of resistance to anti-EGFR antibody therapy based on Caucasian studies. METHODS:...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.